Triple

T15983059
Position Surface form Disambiguated ID Type / Status
Subject Juno Therapeutics E387620 entity
Predicate therapeuticTarget P37016 FINISHED
Object BCMA
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
 E1188120 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: BCMA | Statement: [Juno Therapeutics, therapeuticTarget, BCMA]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: BCMA
Context triple: [Juno Therapeutics, therapeuticTarget, BCMA]
  • A. Kymriah
    Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
  • B. daratumumab
    Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
  • C. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • D. mosunetuzumab (bispecific antibody component)
    Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
  • E. BTK
    BTK is the ICAO airline designator assigned to Batik Air, an Indonesian full-service carrier.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: BCMA
Triple: [Juno Therapeutics, therapeuticTarget, BCMA]
Generated description
BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: BCMA
Target entity description: BCMA (B-cell maturation antigen) is a cell-surface protein expressed on plasma cells and multiple myeloma cells that serves as a key target for immunotherapies such as CAR T-cell treatments.
  • A. Kymriah
    Kymriah is a pioneering CAR-T cell therapy used to treat certain types of blood cancers by genetically modifying a patient’s own immune cells to target and destroy malignant cells.
  • B. daratumumab
    Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
  • C. Kymab
    Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
  • D. mosunetuzumab (bispecific antibody component)
    Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
  • E. BTK
    BTK is the ICAO airline designator assigned to Batik Air, an Indonesian full-service carrier.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d86da94ccc819083d187f5dc6a123e completed April 10, 2026, 3:25 a.m.
NER Named-entity recognition batch_69e1828e9e708190aec0078913bf098a completed April 17, 2026, 12:45 a.m.
NED1 Entity disambiguation (via context triple) batch_69ffc3cdf7848190848e9081027dc027 completed May 9, 2026, 11:31 p.m.
NEDg Description generation batch_69ffc5669c1c81909bacf61c96cb7816 completed May 9, 2026, 11:38 p.m.
NED2 Entity disambiguation (via description) batch_69ffc5c7db1c8190b4e1de6f6e3ce8a0 completed May 9, 2026, 11:39 p.m.
Created at: April 10, 2026, 4:54 a.m.